Constipation Clinical Trial
— GI-ironOfficial title:
Investigating the Effects of Iron on the Gastrointestinal Tract
Many patients that are prescribed iron report gastrointestinal side effects. This research project aims to investigate if the gastrointestinal symptoms of taking iron supplementation are related to changes in gases produced by bacteria in the gastrointestinal tract.
Status | Not yet recruiting |
Enrollment | 155 |
Est. completion date | December 2024 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Written informed consent before participating in the study after being given a full description of the study and prior to any study-specific procedures being performed. 2. Male or non-pregnant female and is age 18 years to 80 years. 3. Can communicate well with the Investigator and to comply with the requirements for the entire study. 4. Capacity to understand written English. 5. New diagnosis iron-deficient anaemia. 6. Prescribed IV iron therapy or oral iron supplementation which contains 65mg elemental iron, two or three times per day for a period of at least 1 month or, will receive 1000mg or 1500mg of intravenous iron, as part of their standard care. 7. Participant agrees to wait until after taking baseline breath samples and completing the IBS-SSS questionnaire before starting their iron therapy. 8. Participant agrees to follow pre-test diet for 24 hours before giving test sample. 9. Participant agrees to refrain from strenuous physical activity on the day of the breath test. 10. Refrain from smoking on the day of the breath test. 11. Agree to complete an overnight fast on the night before the breath test. Food and drink must be withheld until after all breath test samples have been taken. 12. No probiotics for 14 days before the breath test or during the study. 13. Body mass index between 18.5 and 34.9kg/m2 (bounds included). 14. Not antibiotics for 4-weeks before the start of the study or during the study Exclusion Criteria: 1. Using an opioid based medication. 2. Antibiotics in the 4 weeks prior to enrolment. 3. Colonoscopy/sigmoidoscopy in the 1 week prior to enrolment, unless they have taken their baseline breath sample and IBS-SSS questionnaire before completing the required bowel preparation. 4. Diagnosis of any organic gastrointestinal disease, including inflammatory bowel disease, coeliac disease and diverticulitis. 5. Mechanical obstruction of the GI tract. 6. Participant is diabetic. 7. Participant has any hepatic disease. 8. Participant has any disease of the CNS. 9. Participant is involved in this study as an Investigator, sub-Investigator, study coordinator, other study staff, or sponsor member. 10. Previous abdominal or colorectal surgery except appendectomy, cholecystectomy, or hysterectomy. 11. Participant has had iron therapy in the 12 months prior to enrollment. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Sheffield Teaching Hospitals | Sheffield |
Lead Sponsor | Collaborator |
---|---|
The Functional Gut Clinic | Anglia Ruskin University, Sheffield Teaching Hospitals NHS Foundation Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Exploratory | Qualitative and Quantitative data for faecal microorganisms at baseline and 4-weeks since commencing iron therapy. | 4 weeks apart | |
Primary | Breath | Difference in methane levels in breath samples from baseline and 4-weeks since commencing iron therapy. This will be measured in parts per million (ppm). | 4 weeks apart | |
Secondary | Irritable Bowel Syndrome Symptom Severity Score (IBS-SSS) | Comparison in change of IBS-SSS score from baseline to 4 weeks since commencing iron therapy. The minimum score is 0 and maximum score is 500. The greater the score, the worse the severity and frequency of symptoms of abdominal pain and distention, and increased dissatisfaction of overall bowel functioning. | 4 weeks apart | |
Secondary | Stool consistency | Change in stool frequency and form according to the bristol stool chart and abdominal symptoms during the 4 weeks since commencing iron therapy. | 4 weeks apart |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Recruiting |
NCT06292949 -
Clinical Study of Resistant Starch in Improving Constipation
|
N/A | |
Recruiting |
NCT04132661 -
MRI Assessment of Mode of Action of Bisacodyl, Single Dose
|
Phase 4 | |
Completed |
NCT02726295 -
The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study
|
Phase 4 | |
Terminated |
NCT02839889 -
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
|
Phase 4 | |
Recruiting |
NCT02255747 -
Anal Dilatation for Infants and Children With Constipation
|
N/A | |
Completed |
NCT02246647 -
Biomarkers for Intestinal Permeability in Patients With Constipation
|
||
Completed |
NCT01566409 -
Maintenance Treatment for Children With Constipation
|
N/A | |
Completed |
NCT01695915 -
Diurnal Variation in Rectal Diameter
|
N/A | |
Completed |
NCT02658201 -
Ultrafast MRI Imaging to Exclude Constipation
|
N/A | |
Completed |
NCT01710579 -
Normal Values in Ano-rectal 3D High Resolution Manometry
|
N/A | |
Completed |
NCT02863848 -
Effect of Inulin-type Fructans on Constipated Children.
|
N/A | |
Completed |
NCT01411501 -
Efficacy and Safety of Acupuncture for Functional Constipation
|
Phase 3 | |
Completed |
NCT01438567 -
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
|
Phase 3 | |
Completed |
NCT01474499 -
A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation
|
Phase 3 | |
Completed |
NCT01170039 -
The Effectiveness of Lubiprostone in Constipated Diabetics
|
Phase 4 | |
Completed |
NCT00931853 -
Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC).
|
Phase 3 | |
Active, not recruiting |
NCT02442115 -
Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
|
||
Completed |
NCT00994851 -
Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.
|
Phase 3 | |
Terminated |
NCT01003249 -
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
|
Phase 4 |